Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer

Ivanov, Yuri D.; Malsagova, Kristina A.; Goldaeva, Kristina V.; Kapustina, Svetlana I.; Pleshakova, Tatyana O.; Popov, Vladimir P.; Kozlov, Andrey F.; Galiullin, Rafael A.; Shumov, Ivan D.; Enikeev, Dmitry V.; Potoldykova, Natalia V.; Ziborov, Vadim S.; Petrov, Oleg F.; Dolgoborodov, Alexander Y.; Glukhov, Alexander V.; Novikov, Sergey V.; Grabezhova, Victoria K.; Yushkov, Evgeniy S.; Konev, Vladimir A.; Kovalev, Oleg B.; Archakov, Alexander I.

doi:10.3390/s23177527

Sensors

2023

DOI: 10.3390/s23177527

|View full text |Cite

Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer

Yuri D. Ivanov,

Kristina A. Malsagova,

Kristina V. Goldaeva

et al.

Abstract: Prostate cancer (PC) is one of the major causes of death among elderly men. PC is often diagnosed later in progression due to asymptomatic early stages. Early detection of PC is thus crucial for effective PC treatment. The aim of this study is the simultaneous highly sensitive detection of a palette of PC-associated microRNAs (miRNAs) in human plasma samples. With this aim, a nanoribbon biosensor system based on “silicon-on-insulator” structures (SOI-NR biosensor) has been employed. In order to provide biospec… Show more

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mental disorders of the depressive and anxiety spectrum in neuroendocrine tumors: prevalence, pathogenesis, clinical particulars

Kolyago,

Munirova,

Ivanov

et al. 2024

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are a heterogeneous group of slowly progressing tumors from neuroendocrine cells able to secrete biologically active substances. The most striking clinical manifestation of functioning NETs is the carcinoid syndrome, which is caused by serotonin overproduction and is most often associated with hot flashes, diarrhea, and abdominal pain. The prevalence of depressive and anxiety spectrum disorders in NETs patients can amount to 30–50%. The development of depressive and anxiety spectrum disorders in NETs can occur both through a nosogenic mechanism facilitated by a long pre-diagnostic stage, the presence of a serious disease with severe somatic symptoms and resulting significant decrease in quality of life. The mental disorders may be a result of somatogenic factors, which include an imbalance of significant mediators in the central nervous system (in particular, serotonin), as well as chronic inflammation and abnormalities of the body's immune defense. In the treatment of patients with NETs and verified anxiety and depressive disorders, special attention is paid to the safety of prescribing the first-line therapy, the selective serotonin reuptake inhibitors. The side effects of these agents are related to the activity of serotonin receptor agonists in the gut, which results in diarrhea and increased gastrointestinal motility, the symptoms similar to the carcinoid syndrome manifestations. The accumulated evidence allows concluding on the relative safety of serotoninergic antidepressants in NETs patients, but does not exclude some groups of patients with an increased risk of complications related to an additional effect on serotonin metabolism. Current knowledge on the prevalence, pathogenesis and treatment of depressive and anxiety spectrum disorders, comorbid to NETs, are limited and contradictory. Therefore, further studies with a larger patient samples are required to identify key factors of the pathophysiology and manifestation of mental disorders in NETs patients, which would generally facilitate the optimization of their treatment.

show abstract

Mental disorders of the depressive and anxiety spectrum in neuroendocrine tumors: prevalence, pathogenesis, clinical particulars

Kolyago,

Munirova,

Ivanov

et al. 2024

Almanac of Clinical Medicine

View full text Add to dashboard Cite

show abstract

Detection of colorectal cancer associated circular RNAs hsa_circ_0031263, hsa_circ_0072715, and hsa_circ_0136666 in plasma with nanowire chips

Ivanov,

Nevedrova,

Vinogradova

et al. 2024

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Rationale: Colorectal cancer (CRC) is one of the most prevalent oncological diseases with high mortality. Invasive optical (endoscopic) colono- scopy has been recognized as a golden standard for the CRC diagnostics. A promising area is the development of non-invasive tools for CRC diagnosis with circular RNA (circRNA). One of the most sensitive non-invasive tools for detection of cancer RNA markers is considered to be the biosensor methods with the use of nanowire chips with oDNA probes (fragments of DNA oligonucleotides) immobilized on their surface. It has been previously shown that circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 are associated with CRC. Aim: To determine the lower limit of concentration sensitivity of detection of CRC-associated circRNA with nanowire chips with immobilized oDNA probes, to demonstrate the usability of these chips for non-invasive detection of circRNA in plasma in the CRC diagnostics, and to establish the potential for the use of nanowire chips for the early CRC diagnosis. Methods: To ensure biospecific binding of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 (the CRC markers), oDNA probes with the nucleotide sequences complementary to the target circRNA have been immobilized on the nanowire surface. At the study step 1, we detected the lower concentration limit for detection of the target molecules with the use of their analogues, i.e. synthetic model oDNA with the nucleotide sequences complementary to oDNA probes. At the study step 2, we used the nanowire chips with immobilized oDNA probes to detect the circRNA in plasma of the patients with confirmed CRC. Plasma samples from non-cancer patients were used as controls. Results: The lower concentration limit for the detection of DNA analogues of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 with nanowire chips with oDNA probes was 10-16 М. The analysis of total RNA isolated from plasma of the CRC patients showed a significant increase in the signal from the sensory elements of the nanowire chip. The analysis of plasma samples from the non-cancer patients, the nanowire signal changes were non-significant indicating the absence of detectable concentrations of the circRNA in plasma of the non-cancer patients. Conclusion: We have identified the minimal detectable concentration of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1, associated to the development of CRC, with nanowire chips with immobilized oDNA probes: it was 10-16 М. The experiment showed the usability of such nanowire chips for non-invasive detection of the given circRNA markers in total RNA samples isolated from plasma of CRC patients.

show abstract

Nanotechnology-based Assays for the Detection of Cancer through Sputum

Singh

2023

CAC

View full text Add to dashboard Cite

Cancer remains a formidable global health challenge, underscoring the critical need for early and accurate diagnostic tools. In recent years, nanotechnology has emerged as a promising frontier in cancer detection, offering innovative approaches to enhance sensitivity, specificity, and convenience in diagnostics. This comprehensive review delves into the intersection of nanotechnology and sputum-based assays for cancer detection. Sputum, a readily accessible biomarker source, has gained increasing attention due to its potential to house early cancer biomarkers. By harnessing the unique properties of nanoparticles, this review explores how nanotechnology is revolutionizing sputum- based cancer detection. We examine the intrinsic attributes of sputum as a diagnostic fluid, the diverse applications of nanoparticles, and the evolving landscape of cancer-specific biomarkers. Moreover, we provide insights into various nanotechnology assay techniques and their clinical implications while highlighting the challenges and future prospects in this dynamic field. This review aims to elucidate the transformative impact of nanotechnology on cancer diagnostics through sputum, offering a roadmap towards earlier and more accurate cancer detection.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer

Cited by 3 publications

References 59 publications

Mental disorders of the depressive and anxiety spectrum in neuroendocrine tumors: prevalence, pathogenesis, clinical particulars

Mental disorders of the depressive and anxiety spectrum in neuroendocrine tumors: prevalence, pathogenesis, clinical particulars

Detection of colorectal cancer associated circular RNAs hsa_circ_0031263, hsa_circ_0072715, and hsa_circ_0136666 in plasma with nanowire chips

Nanotechnology-based Assays for the Detection of Cancer through Sputum

Contact Info

Product

Resources

About